Published in Nat Rev Neurosci on November 01, 2007
Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A (2012) 5.67
High-potency cannabis and the risk of psychosis. Br J Psychiatry (2009) 2.41
Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry (2012) 2.07
Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids. Science (2013) 2.04
Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc (2012) 1.79
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull (2009) 1.47
The relationship between bipolar disorder and cannabis use in daily life: an experience sampling study. PLoS One (2015) 1.42
Gene-environment interplay between cannabis and psychosis. Schizophr Bull (2008) 1.34
Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci (2009) 1.32
Cannabinoids in health and disease. Dialogues Clin Neurosci (2007) 1.28
Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther (2010) 1.24
Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction. Ann N Y Acad Sci (2010) 1.17
Origin, early commitment, migratory routes, and destination of cannabinoid type 1 receptor-containing interneurons. Cereb Cortex (2009) 1.17
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci (2012) 1.15
Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res (2008) 1.13
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. J Exp Med (2012) 1.11
Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience (2010) 1.10
Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol (2010) 1.10
Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience (2010) 1.01
Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res (2011) 1.01
Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology (2010) 0.97
Should burden of disease estimates include cannabis use as a risk factor for psychosis? PLoS Med (2009) 0.94
Chronic adolescent exposure to Δ-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology (2010) 0.93
AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology (2011) 0.92
Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov (2012) 0.91
Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. Schizophr Bull (2015) 0.91
Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology (2011) 0.90
Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology (2010) 0.89
Analysis of Cannabinoids and Their Metabolites in Human Urine. Anal Chem (2015) 0.89
The endocannabinoid system: directing eating behavior and macronutrient metabolism. Front Psychol (2015) 0.89
Pursuing paradoxical proconvulsant prophylaxis for epileptogenesis. Epilepsia (2009) 0.89
Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. Schizophr Res (2012) 0.88
Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex. Cereb Cortex (2009) 0.87
Urinary concentrations of PAH and VOC metabolites in marijuana users. Environ Int (2015) 0.85
Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci (2013) 0.84
Rising Threat; Bonsai. Turk J Emerg Med (2016) 0.84
Decanalization, brain development and risk of schizophrenia. Transl Psychiatry (2011) 0.83
Altering endocannabinoid neurotransmission at critical developmental ages: impact on rodent emotionality and cognitive performance. Front Behav Neurosci (2012) 0.83
The effect of cannabis use on memory function: an update. Subst Abuse Rehabil (2013) 0.83
Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry (2016) 0.82
Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Front Neurosci (2013) 0.82
Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer (2015) 0.82
Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex. Neuropsychopharmacology (2011) 0.81
Marijuana use: neuroscience perspective. Croat Med J (2014) 0.81
Circuits controlling energy balance and mood: inherently intertwined or just complicated intersections? Cell Metab (2014) 0.78
Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System. Neuropsychopharmacology (2016) 0.77
Disruption of IFN-gamma- mediated antiviral activity in neurons: the role of cannabinoids. Viral Immunol (2008) 0.77
MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol Med (2012) 0.77
Cannabis and Psychosis: What Can Daily Diaries Tell Us About Who is Vulnerable? Prim psychiatry (2009) 0.76
Endocannabinoids and striatal function: implications for addiction-related behaviours. Behav Pharmacol (2015) 0.76
Modeling Illicit Drug Use Dynamics and Its Optimal Control Analysis. Comput Math Methods Med (2015) 0.75
Cannabis Use in Adolescence and Young Adulthood: A Review of Findings from the Victorian Adolescent Health Cohort Study. Can J Psychiatry (2016) 0.75
Association Between Use of Cannabis in Adolescence and Weight Change into Midlife. PLoS One (2017) 0.75
Lifetime use of cannabis from longitudinal assessments, cannabinoid receptor (CNR1) variation, and reduced volume of the right anterior cingulate. Psychiatry Res (2016) 0.75
Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings. Eur Arch Psychiatry Clin Neurosci (2013) 0.75
Mismatch Negativity and P50 Sensory Gating in Abstinent Former Cannabis Users. Neural Plast (2016) 0.75
Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biol Psychiatry (2015) 0.75
Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition. Curr Addict Rep (2017) 0.75
Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology (Berl) (2014) 0.75
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ (2011) 3.84
Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review. J Psychopharmacol (2007) 1.78
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2009) 1.62
Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr Res (2009) 1.48
Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci (2007) 1.42
Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. Clin Pharmacokinet (2015) 1.40
Gene-environment interplay between cannabis and psychosis. Schizophr Bull (2008) 1.34
Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav Rev (2011) 1.31
Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model. Psychol Med (2007) 1.31
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (2012) 1.29
Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr Res (2010) 1.26
Childhood victimisation and developmental expression of non-clinical delusional ideation and hallucinatory experiences: victimisation and non-clinical psychotic experiences. Soc Psychiatry Psychiatr Epidemiol (2006) 1.23
Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol (2008) 1.13
Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr Res (2010) 1.13
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia. Hum Mol Genet (2010) 1.08
The copy number variant involving part of the alpha7 nicotinic receptor gene contains a polymorphic inversion. Eur J Hum Genet (2008) 1.06
Cannabis use and psychiatric and cogitive disorders: the chicken or the egg? Curr Opin Psychiatry (2007) 1.04
Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun (2012) 1.02
Association between symptom dimensions and categorical diagnoses of psychosis: a cross-sectional and longitudinal investigation. Schizophr Bull (2013) 1.01
Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLoS One (2013) 0.98
Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psychosis: an experience-sampling study. Am J Med Genet B Neuropsychiatr Genet (2008) 0.98
Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis. Psychoneuroendocrinology (2011) 0.98
Vitamin D deficiency in first episode psychosis: a case-control study. Schizophr Res (2013) 0.94
Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci (2011) 0.94
Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol (2010) 0.93
Positional pathway screen of wnt signaling genes in schizophrenia: association with DKK4. Biol Psychiatry (2007) 0.89
Prevalence of bullying victimisation amongst first-episode psychosis patients and unaffected controls. Schizophr Res (2013) 0.88
COMT Val158Met moderation of stress-induced psychosis. Psychol Med (2007) 0.88
A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. Biol Psychiatry (2013) 0.87
Application of microscale-preparative multidimensional gas chromatography with nuclear magnetic resonance spectroscopy for identification of pure methylnaphthalenes from crude oils. J Chromatogr A (2008) 0.86
Social disadvantage: cause or consequence of impending psychosis? Schizophr Bull (2012) 0.85
Method for small-molecule discovery based on microscale-preparative multidimensional gas chromatography isolation with nuclear magnetic resonance spectroscopy. Anal Chem (2008) 0.85
What is the mechanism whereby cannabis use increases risk of psychosis? Neurotox Res (2008) 0.84
[18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict Biol (2013) 0.84
Effect of COMT genotype on aggressive behaviour in a community cohort of schizophrenic patients. Neurosci Lett (2011) 0.83
Assimilation of polybrominated diphenyl ethers from microplastics by the marine amphipod, Allorchestes compressa. Environ Sci Technol (2014) 0.82
What can we learn about schizophrenia from studying the human model, drug-induced psychosis? Am J Med Genet B Neuropsychiatr Genet (2013) 0.82
Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res (2013) 0.82
Is neuregulin 1 involved in determining cerebral volumes in schizophrenia? Preliminary results showing a decrease in superior temporal gyrus volume. Neuropsychobiology (2012) 0.82
A novel method for reducing the effect of tonic muscle activity on the gamma band of the scalp EEG. Brain Topogr (2012) 0.82
Multiple component isolation in preparative multidimensional gas chromatography with characterisation by mass spectrometry and nuclear magnetic resonance spectroscopy. J Chromatogr A (2009) 0.81
Quantitative analysis of delta9-tetrahydrocannabinol in preserved oral fluid by liquid chromatography-tandem mass spectrometry. J Chromatogr A (2005) 0.81
Non-replication of interaction between cannabis use and trauma in predicting psychosis. Schizophr Res (2011) 0.80
Assessing the hydrocarbon degrading potential of indigenous bacteria isolated from crude oil tank bottom sludge and hydrocarbon-contaminated soil of Azzawiya oil refinery, Libya. Environ Sci Pollut Res Int (2014) 0.80
The coherence of the evidence linking cannabis with psychosis. Psychol Med (2008) 0.79
Investigation of folic acid stability in fortified instant noodles by use of capillary electrophoresis and reversed-phase high performance liquid chromatography. J Chromatogr A (2008) 0.79
Metabolomic analysis of Cryptosporidium parvum oocysts in water: a proof of concept demonstration. Environ Pollut (2012) 0.78
Does cannabidiol protect against the negative effects of THC? Br J Psychiatry (2010) 0.78
Persecutory ideation and a history of cannabis use. Schizophr Res (2013) 0.78
Analysis of the volatile organic compounds from leaves, flower spikes, and nectar of Australian grown Agastache rugosa. BMC Complement Altern Med (2014) 0.77
Insight and suicidality in first-episode psychosis: understanding the influence of suicidal history on insight dimensions at first presentation. Early Interv Psychiatry (2013) 0.76
One-pot microwave derivatization of target compounds relevant to metabolomics with comprehensive two-dimensional gas chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.76
Fecal Microbiota and Metabolome in a Mouse Model of Spontaneous Chronic Colitis: Relevance to Human Inflammatory Bowel Disease. Inflamm Bowel Dis (2016) 0.76
Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis. Psychopharmacology (Berl) (2014) 0.76
Cannabis consumption and risk of developing schizophrenia: myth or reality? Epidemiol Psichiatr Soc (2006) 0.76
Summary of the 1st Schizophrenia International Research Society Conference oral sessions, Venice, Italy, June 21-25, 2008: the rapporteur reports. Schizophr Res (2008) 0.76
Cannabis in the arm: what can we learn from intravenous cannabinoid studies? Curr Pharm Des (2012) 0.75
Do psychosis patients with poor insight show implicit awareness on the emotional stroop task? Psychopathology (2013) 0.75
Development of a switchable multidimensional/comprehensive two-dimensional gas chromatographic analytical system. J Chromatogr A (2010) 0.75
Qualitative and quantitative study of nitrogen-containing compounds in heavy gas oil using comprehensive two-dimensional gas chromatography with nitrogen phosphorus detection. J Sep Sci (2007) 0.75
Fear knot. Neurobiological disruption of long-term fear memory. Br J Psychiatry (2002) 0.75
Why do psychotic patients take cannabis? Psychol Med (2008) 0.75
Characterization of tetra-aryl benzene isomers by using preparative gas chromatography with mass spectrometry, nuclear magnetic resonance spectroscopy, and X-ray crystallographic methods. Anal Chem (2010) 0.75
Effects of variation in modulator temperature during cryogenic modulation in comprehensive two-dimensional gas chromatography. J Sep Sci (2009) 0.75
A candidate reference method using ICP-MS for sweat chloride quantification. Clin Chem Lab Med (2016) 0.75
Erratum: Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case-control study. NPJ Schizophr (2015) 0.75